• Return to Headlines

Acadia Pharmaceuticals Shares Down 22.1% Since SmarTrend's Sell Call (ACAD)

By David Diaz

SmarTrend identified a Downtrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on March 21st, 2017 at $36.14. In approximately 3 months, Acadia Pharmaceuticals has returned 22.10% as of today's recent price of $28.15.

In the past 52 weeks, shares of Acadia Pharmaceuticals have traded between a low of $16.64 and a high of $51.99 and are now at $28.15, which is 69% above that low price. Over the past week, the 200-day moving average (MA) has gone down 1.2% while the 50-day MA has advanced 3.1%.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company is currently working on the treatment of induced dysfunction in Parkinson's disease ,schizophrenia, neuropathic pain and glaucoma.

SmarTrend will continue to scan these moving averages and a number of other proprietary indicators for any changes in momentum for shares of Acadia Pharmaceuticals.

Log in and add Acadia Pharmaceuticals (ACAD) to your watchlist today so you can receive a real-time alert when the shares are about to change trend.

Keywords: spotlights acadia pharmaceuticals

Ticker(s): ACAD